At the recent Malaysian Osteoporosis Society 2016 Clinical Practice Guideline (CPG) Meeting held on the 8th of October 2016 at Ibis Styles Ipoh, Dr Hew Fen Lee and Professor Dr Chan Siew Pheng presented clinical guidance on the management of osteoporosis, and discussed whether the benefits of treatment outweigh the risks.
At the Diabetes Asia 2016 Conference organized by the National Diabetes Institute, Professor Jean Claude Mbanya presented the case for why gliclazide modified release (MR; Diamicron® MR, Servier) should be the treatment of choice for early and aggressive control of type 2 diabetes (T2D).
BASALOG – Insulin glargine (rDNA) 100 IU/mL soln for inj (cartridge) – CCM Pharmaceuticals
INVOKANA – Canagliflozin hemihydrate 100 mg and 300 mg FC tab – Johnson & Johnson (Janssen)
Preventing hypertension, diabetes, and obesity, which are the major risk factors for heart failure (HF), by ages 45 and 55 years may lower risks of incident HF and prolong HF-free survival, suggests data from the Cardiovascular Disease Lifetime Risk Pooling Project.
Part IV: Systolic Blood Pressure (BP) and the Combination of Indapamide Sustained Release (SR) and Amlodipine, an Endocrinologist’s Point of View
The prevalence of hypertension is on the rise in Malaysia and many patients require more than one medication to control their BP. However, treatment adherence is a common issue in patient management, particularly when it comes to patients with multiple morbidities requiring numerous medications.1 In this interview, MIMS Doctor spoke to a distinguished endocrinologist about systolic hypertension, diabetes and patient compliance.
A 55-year-old man presented with almost one year history of heat intolerance, mild palpitation and significant weight loss. Free T3 and T4 were elevated with normal TSH. Patient had suboptimal response to carbimazole therapy.
The Malaysian drug armamentarium for diabetes welcomed its most recent addition with the launch of the first and only metformin XR + sodium glucose cotransporter (SGLT) 2 inhibitor (Xigduo XR®, AstraZeneca) combination therapy in Malaysia. The glittering event witnessed four esteemed speakers share their views on the need to intensify the battle against the disease.
At the 7th Annual Congress of the Malaysian Endocrine & Metabolic Society (MAC7), Professor Dr Chan Siew Pheng and Dr Gavin Tan spoke on the recent evidence to improve residual CV risk and DR respectively, in type 2 diabetes mellitus (T2DM). Highlights of their presentations are summarized below.
With the recent introduction of the new dapagliflozin-metformin XR combination tablet in Malaysia, two eminent speakers with vast experience in diabetes management discussed current evidence and their own experience in using the sodium-glucose cotransporter 2 (SGLT2) inhibitor.